[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540334":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":212,"collaborators":24,"id":214,"slug":215,"hasResults":216,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":24,"eligibilityCriteria":220,"healthyVolunteers":216,"sex":221,"minAge":222,"maxAge":24,"enrollmentInfo":223,"targetDuration":24,"studyType":226,"phases":227,"briefSummary":229,"conditions":230,"keywords":24,"overallStatus":166,"whyStopped":24,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},{"fullName":5,"class":6},"Cybrexa Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CBX-12 - 125mg\u002Fm2 q21d","EXPERIMENTAL","125mg\u002Fm2 CBX-12 administered by intravenous (IV) infusion every 21 days. Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity.",[13],"Drug: CBX-12",{"label":15,"type":10,"description":16,"interventionNames":17},"CBX-12 - 100mg\u002Fm2 q21d","100mg\u002Fm2 CBX-12 administered by intravenous (IV) infusion every 21 days. Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","CBX-12","CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.",[15,9],null,[26],{"name":27,"affiliation":5,"role":28},"Michael Needle, MD","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Clinical Operations Trial Team","CONTACT","860-717-2731","clinicalstudies@cybrexa.com",[36,50,60,70,80,90,99,109,119,129,138,144,154,164,179,193,202],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":24},"Honor Health","WITHDRAWN","Scottsdale","Arizona","85260","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-111.89903,33.50921,{"lat":48,"lon":47},{"facility":51,"status":52,"city":53,"state":40,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":24},"Arizona Oncology Associates","ACTIVE_NOT_RECRUITING","Tucson","85711",{"type":45,"coordinates":56},[57,58],-110.92648,32.22174,{"lat":58,"lon":57},{"facility":61,"status":52,"city":62,"state":63,"zip":64,"country":42,"countryCode":43,"cosmosGeoPoint":65,"geoPoint":69,"contacts":24},"Usc Norris Comprehensive Cancer Center","Los Angeles","California","90033",{"type":45,"coordinates":66},[67,68],-118.24368,34.05223,{"lat":68,"lon":67},{"facility":71,"status":52,"city":72,"state":73,"zip":74,"country":42,"countryCode":43,"cosmosGeoPoint":75,"geoPoint":79,"contacts":24},"Yale University School of Medicine","New Haven","Connecticut","06510",{"type":45,"coordinates":76},[77,78],-72.92816,41.30815,{"lat":78,"lon":77},{"facility":81,"status":52,"city":82,"state":83,"zip":84,"country":42,"countryCode":43,"cosmosGeoPoint":85,"geoPoint":89,"contacts":24},"D&H Cancer Research Center","Margate","Florida","33063",{"type":45,"coordinates":86},[87,88],-80.20644,26.24453,{"lat":88,"lon":87},{"facility":91,"status":52,"city":92,"state":83,"zip":93,"country":42,"countryCode":43,"cosmosGeoPoint":94,"geoPoint":98,"contacts":24},"South Florida Gynecology","Tampa","33606",{"type":45,"coordinates":95},[96,97],-82.45843,27.94752,{"lat":97,"lon":96},{"facility":100,"status":38,"city":101,"state":102,"zip":103,"country":42,"countryCode":43,"cosmosGeoPoint":104,"geoPoint":108,"contacts":24},"Northwest Cancer Centers","Dyer","Indiana","46311",{"type":45,"coordinates":105},[106,107],-87.52171,41.4942,{"lat":107,"lon":106},{"facility":110,"status":52,"city":111,"state":112,"zip":113,"country":42,"countryCode":43,"cosmosGeoPoint":114,"geoPoint":118,"contacts":24},"Norton Cancer Institute","Louisville","Kentucky","40202",{"type":45,"coordinates":115},[116,117],-85.75941,38.25424,{"lat":117,"lon":116},{"facility":120,"status":52,"city":121,"state":122,"zip":123,"country":42,"countryCode":43,"cosmosGeoPoint":124,"geoPoint":128,"contacts":24},"Women's Cancer Care","Covington","Louisiana","70433",{"type":45,"coordinates":125},[126,127],-90.10042,30.47549,{"lat":127,"lon":126},{"facility":130,"status":52,"city":131,"state":131,"zip":132,"country":42,"countryCode":43,"cosmosGeoPoint":133,"geoPoint":137,"contacts":24},"Pci Nyu Langone Health","New York","10016",{"type":45,"coordinates":134},[135,136],-74.00597,40.71427,{"lat":136,"lon":135},{"facility":139,"status":52,"city":131,"state":131,"zip":140,"country":42,"countryCode":43,"cosmosGeoPoint":141,"geoPoint":143,"contacts":24},"Albert Einstein College of Medicine Montefiore Medical","10021",{"type":45,"coordinates":142},[135,136],{"lat":136,"lon":135},{"facility":145,"status":52,"city":146,"state":147,"zip":148,"country":42,"countryCode":43,"cosmosGeoPoint":149,"geoPoint":153,"contacts":24},"University Hospitals Seidman Cancer Center","Cleveland","Ohio","44106",{"type":45,"coordinates":150},[151,152],-81.69541,41.4995,{"lat":152,"lon":151},{"facility":155,"status":52,"city":156,"state":157,"zip":158,"country":42,"countryCode":43,"cosmosGeoPoint":159,"geoPoint":163,"contacts":24},"Oncology Associates of Oregon","Eugene","Oregon","97401",{"type":45,"coordinates":160},[161,162],-123.08675,44.05207,{"lat":162,"lon":161},{"facility":165,"status":166,"city":167,"state":168,"zip":169,"country":42,"countryCode":43,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Allegheny Singer Research Institute D\u002FB\u002FA Ahn Research Institution","RECRUITING","Pittsburgh","Pennsylvania","15212",{"type":45,"coordinates":171},[172,173],-79.99589,40.44062,{"lat":173,"lon":172},[176],{"name":177,"role":32,"phone":178,"phoneExt":24,"email":24},"Shannon Buono","412-578-4216",{"facility":180,"status":166,"city":181,"state":182,"zip":183,"country":42,"countryCode":43,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"Mary Crowley Cancer Research","Dallas","Texas","75251",{"type":45,"coordinates":185},[186,187],-96.80667,32.78306,{"lat":187,"lon":186},[190],{"name":191,"role":32,"phone":192,"phoneExt":24,"email":24},"Cristina Laviada","972-566-3044",{"facility":194,"status":52,"city":195,"state":182,"zip":196,"country":42,"countryCode":43,"cosmosGeoPoint":197,"geoPoint":201,"contacts":24},"Texas Oncology- Gulf Coast","The Woodlands","77380",{"type":45,"coordinates":198},[199,200],-95.48938,30.15799,{"lat":200,"lon":199},{"facility":203,"status":52,"city":204,"state":205,"zip":206,"country":42,"countryCode":43,"cosmosGeoPoint":207,"geoPoint":211,"contacts":24},"Multicare Institute For Research & Innovation","Tacoma","Washington","98405",{"type":45,"coordinates":208},[209,210],-122.44429,47.25288,{"lat":210,"lon":209},{"type":213,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100540334","phase-2-a-study-of-cbx-12-in-subjects-with-platinum-resistant-or-refractory-ovarian-cancer-100540334",false,"NCT06315491","A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer","A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer","Inclusion Criteria:\n\n* Subjects must have histologically- or cytologically-diagnosed epithelial high-grade serous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer that is refractory to prior therapy and must have platinum-resistant disease defined as:\n\n  * Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring ≤ 26 weeks after their last dose of platinum.\n  * Patients who have progressed following a second course of a platinum based regimen.\n  * Subjects may have up to 2 additional systemic regimens for advanced or metastatic disease. Maintenance regimens (e.g., with a PARP inhibitor or bevacizumab) are not considered separate regimens.\n* Age greater than or equal to 18 years at the time of signing the informed consent form (ICF).\n* Has measurable disease per RECIST 1.1.\n* Has provided written informed consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate liver, renal, hematologic, pulmonary and coagulation function.\n\nExclusion Criteria:\n\n* Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.\n* Subjects who are currently receiving any other anticancer or investigational agent(s).\n* Clinically significant intercurrent disease.\n* Active human immunodeficiency virus (HIV) infection.\n* Active hepatitis B or C infection.","FEMALE","18 Years",{"count":224,"type":225},40,"ESTIMATED","INTERVENTIONAL",[228],"PHASE2","The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg\u002Fm2 every 21 days or 100 mg\u002Fm2 every 21 days.",[231,232],"Platinum-resistant Ovarian Cancer","Refractory Ovarian Carcinoma","2025-10-02",{"date":235,"type":236},"2025-10-06","ACTUAL",{"date":238,"type":236},"2024-09-25",{"date":240,"type":225},"2025-10",{"name":5,"class":6},17]